.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,846,468

« Back to Dashboard

Details for Patent: 7,846,468

Title:Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
Abstract: Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.
Inventor(s): Wong; Vernon G. (Menlo Park, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Filing Date:Nov 03, 2008
Application Number:12/264,142
Claims:1. An intraocular, bioerodible drug delivery system comprising anecortave acetate and a bioerodible polymer, wherein the system is effective in releasing the anecortave acetate into the eye over a period of at least about 3 weeks, and wherein the intraocular, bioerodible drug delivery system is a single pellet or a single extruded filament.

2. The drug delivery system of claim 1 wherein the anecortave acetate is homogenously distributed in the bioerodible polymer.

3. The drug delivery system of claim 1, wherein the bioerodible polymer is a polylactic acid polyglycolic acid (PLGA) copolymer.

4. The drug delivery system of claim 1, wherein the anecortave acetate is present in an amount in a range of about 10% to 90% by weight.

5. The drug delivery system of claim 2, wherein the anecortave is present in an amount in a range of about 50% to about 80% by weight.

6. An intraocular, bioerodible drug delivery system comprising anecortave acetate and a polylactic acid polyglycolic acid (PLGA) copolymer, wherein the system is effective in releasing the anecortave acetate into the eye over a period of at least about 3 weeks, and wherein the intraocular, bioerodible drug delivery system is a single pellet or a single extruded filament, wherein the anecortave acetate is present homogenously distributed in the polymer, and wherein the anecortave acetate is present in an amount in a range of about 10% to 90% by weight.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc